Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and III studies

European Urology, Supplement

Volumn 1, Issue 3, 2002, Pages 21-27

  Ralph, D J ^a   Sleep, D J ^b   Perdok, R J ^b   Padley, R J ^b  

^a 2A Maple House   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Apomorphine SL; Cross study; Erectile dysfunction; Tolerability

Indexed keywords

APOMORPHINE;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HEADACHE; HEART INFARCTION; HUMAN; HYPOTENSION; NAUSEA; OUTCOMES RESEARCH; PRIAPISM; PRIORITY JOURNAL; SOMNOLENCE; STROKE; SWEATING; SYNCOPE; VASODILATATION; VERTIGO; YAWNING;

EID: 0036590013     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00010-6     Document Type: Article

References (20)

1. Mathiessen A, Wright CRA. Researches into the chemical constitution of the opium bases. Part I. On the action of hydrochloric acid on morphine. Proc. R Soc London B Biol Sci 1869:17:455-62.
2. Heaton JPW, Morales A, Adams MA, Johnston B, El-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-6.
3. Wagner G. Apomorphine SL (Uprima®): A new treatment for the management of erectile dysfunction. Int J Impot Res 2001;13(Suppl 3): S1-2.
4. Morales A. Apomorphine to Uprima: The development of a practical erectogenic drug: A personal perspective. Int J Impot Res 2001; 13(Suppl 3):S29-34.
5. Heaton JPW. Apomorphine: An update of clinical trials. Int J Impot Res 2000;12(Suppl 4):S67-73.
6. Dula E, Keating W, Siami PF, Edmonds A, O'Neil J, Butler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology 2000;56:130-5.
7. Dula E, Bukofzer S, Perdok R, George M, and the Apomorphine Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:558-64.
8. Heaton JPW. Characterising the benefit of apomorphine SL (Uprima®) as an optimised treatment for representative populations with erectile dysfunction. Int J Impot Res 2001;3(Suppl 3): S35-9.
9. Argiolas A, Hedlund H. The pharmacology and clinical pharmaco-kinetics of apomorphine SL. Br J Urol Int 2001;88(Suppl 3):18-21.
10. Mulhall JP, Bukofzer S, Edmonds AL, George M, and the Apomorphine Study Group. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther 2001;23:1260-71.
11. Physicians' Desk Reference, 56th ed. Montvale (NJ): Medical Economics Company Inc., 2002. p. 1680.
12. Adams MA, Perdok RJ, Padley RJ, Sleep DJ. Safety and tolerability of apomorphine SL in men with cardiovascular disorders. Eur Urol Suppl 2002;1:28-32.
13. Chew KK, Stuckey BGA, Thompson PL. Erectile dysfunction, sildenafil and cardiovascular risk. Med J Aust 2000;172:279-83.
14. Abbott data on file.
15. First International Consultation on Erectile Dysfunction. World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societé Internationale d'Urologie (SIU), Paris, 1-3 July, 1999.
16. Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11:59-74.
17. Barone JA. Domperidone: A peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429-40.
18. Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima®). Int J Impot Res 2001;13(Suppl 3):S40-4.
19. Stief C, Padley RJ, Perdok RJ, Sleep DJ. Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: Pooled data from three placebo-controlled fixed-dose crossover studies. Eur Urol Suppl 2002; 1(3):12-20.
20. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40-69 years old: Longitudinal results from the MMAS. J Urol 2000;163: 460-3.